Bisphosphonates: From the laboratory to the clinic and back again

Bone

Volumn 25, Issue 1, 1999, Pages 97-106

  Russell, R G G ^a   Rogers, M J ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Bisphosphonates; Bone metastases; Bone resorption; Myeloma; Osteoclast; Osteoporosis; Protein prenylation

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; GUANOSINE TRIPHOSPHATASE; HYDROXYAPATITE; IBANDRONIC ACID; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; TILUDRONIC ACID;

APOPTOSIS; BONE MASS; BONE METASTASIS; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; FRACTURE; HUMAN; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MYELOMA; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PHARMACOPHORE; PRENYLATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0033065233     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00116-7     Document Type: Article

References (106)

1. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 337:1997;381-387.
2. Adami S., Bhalla A.K., Dorizzi R., et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 41:1987;326-331.
3. Adami S., Zamberlan N. Adverse effects of bisphosphonates. Drug Safety. 14:1996;158-170.
4. Amin D., Cornell S.A., Gustafson S.K., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res. 33:1992;1657-1663.
5. Amin D., Cornell S.A., Perrone M.H., Bilder G.E. 1-hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res. 46:1996;759-762.
6. Auriola S., Frith J., Rogers M.J., Koivuniemi A., Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chrom B. 704:1997;187-195.
7. Azuma Y., Sato H., Oue Y., et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone. 16:1995;235-245.
8. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 348:1996;1535-1541.
9. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 334:1996;488-493.
10. Bijvoet, O., Fleisch, H., Canfield, R. E., and Russell, R. G. G., Eds. Bisphosphonates on Bone. Elsevier Science B. V.: Amsterdam; 1995; paper 1-455.
11. Boonekamp P.M., van der Wee-Pals L.J.A., van Wijk-van Lennep M.L.L., Wil Thesing C., Bijvoet O.L.M. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1:1986;27-39.
12. Breuil V., Cosman F., Stein L., et al. Human osteoclast formation and activity in vitro effects of alendronate . J Bone Miner Res. 13:1998;1721-1729.
13. Carano A., Teitelbaum S.A., Konsek J.D., Schlesinger P.H., Blair H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 85:1990;456-461.
14. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 100:1997;1475-1480.
15. Coxon F.P., Benford H.L., Russell R.G.G., Rogers M.J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol. 54:1998;631-638.
16. + ATPase. J Bone Miner Res. 11:1996;1498-1507.
17. DeGroen P.C., Lubbe D.F., Hirsch L.J., et al. Esophagitis associated with the use of alendronate. N Engl J Med. 355:1996;1016-1021.
18. Delmas P.D., Meunier P.J. The management of Paget's disease of bone. N Engl J Med. 336:1997;558-566.
19. Diel I.J., Solomayer E.-F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339:1998;357-363.
20. Douglas D.L., Russell R.G.G., Preston C.J., et al. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1:1980;1043-1047.
21. Ebetino F.H., Bayless A.V., Amburgey J., Ibbotson K.J., Dansereau S., Ebrahimpour A. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus, Sulfur and Silicon. 109/110:1996;217-220.
22. Ebetino F.H., Francis M.D., Rogers M.J., Russell R.G.G. Etidronate. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharma. 9:1998;233-243.
23. Endo N., Rutledge S.J., Opas E.E., Vogel R., Rodan G.A., Schmidt A. Human protein tyrosine phosphatases alternative splicing and inhibition by bisphosphonates . J Bone Miner Res. 11:1996;535-543.
24. Felix R., Russell R.G.G., Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta. 429:1976;429-438.
25. Fisher J.E., Rogers M.J., Halasy J.M., et al. Mechanism of action of alendronate geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro . Proc Natl Acad Sci USA. 96:1999;133-138.
26. 2MBP-coated bone. Bone Miner. 6:1986;33-43.
27. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient, Third Edition. 1997;The Parthenon Publishing Group, New York.
28. Fleisch H. Bisphosphonates mechanisms of action . Endocr Rev. 19:1998;80-100.
29. Fleisch H., Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol. 203:1962;671-675.
30. Fleisch H., Neuman W.F. Mechanisms of calcification role of collagen, polyphosphates, and phosphatase . Am J Physiol. 200:1961;1296-1300.
31. Francis M.D., Russell R.G.G., Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 165:1969;1264-1266.
32. Fleisch H., Russell R.G.G., Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 165:1969;1262-1264.
33. Fleisch H., Russell R.G.G., Bisaz S., Muhlbauer R.C., Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest. 1:1970;12-18.
34. Fleisch H., Russell R.G.G., Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 212:1966;901-903.
35. Fogelman I., Bessent R.G., Turner J.F., Citrin D.L., Boyce I.T., Greig W.R. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 19:1978;270-275.
36. Francis M.D., Fogelman I. 99mTc-diphosphonate uptake mechanisms on bone. Fogelman I. Bone Scanning in Clinical Practice. 1987;1-6 Springer Verlag, London.
37. Francis R.M. Oral bisphosphonates in the treatment of osteoporosis a review . Curr Ther Res. 56:1998;831-851.
38. Frith J.C., Coxon F.P., Auriola S., et al. The molecular mechanism of action of clodronate in osteoclasts. J Bone Miner Res. 23:(Suppl.):1998;551.
39. Frith J.C., Mönkkönen J., Blackburn G.M., Russell R.G.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 12:1996;1358-1367.
40. Garnero P., Shih W.J., Gineyts E., Karpf D.G., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1994;1693-1700.
41. Geddes A.D., D'Souza S.M., Ebetino F.H., Ibbotson K.J. Bisphosphonates structure-activity relationships and therapeutic implications . Bone Miner Res. 8:1994;265-306.
42. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 33:1998;947-952.
43. Hall A. Rho GTPases and the actin cytoskeleton. Science. 279:1998;509-514.
44. Hughes D.E., MacDonald B.R., Russell R.G.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 83:1989;1930-1935.
45. Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 10:1995;1478-1487.
46. Ito M., Chokki M., Ogino Y., et al. Comparison of the cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tiss Int. 63:1998;143-147.
47. Johnson, S. and Johnson, F. N., Eds. Etidronate in Osteoporosis. Rev Contemp Pharm 9:1-292; 1998.
48. Lerner U.H., Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone. 8:1987;179-189.
49. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
50. Löwik C.W.G.M., van der Pluijm G., van der Wee-Pals L.J.A., Bloys van Treslong-de Groot H., Bijvoet O.L.M. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts the effect of a bisphosphonate . J Bone Miner Res. 3:1988;185-192.
51. Luckman S.P., Coxon F.P., Ebetino F.H., Russell R.G.G., Rogers M.J. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation evidence from structure-activity relationships in J774 macrophages . J Bone Miner Res. 13:1998;1668-1678.
52. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 13:1998;581-589.
53. Marshall C. Protein prenylation a mediator of protein-protein interactions . Science. 259:1993;1865-1866.
54. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 19:1996;281-290.
55. McCloskey E.V., MacLennan I.C.M., Drayson M., Chapman C., Dunn J., Kanis J.A. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 100:1998;317-325.
56. Mundy G.R., Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 339:1998;398-400.
57. Murakami H., Takahashi N., Sasaki T., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts tiludronate preferentially affects polarized osteoclasts having ruffled borders . Bone. 17:1995;137-144.
58. Murakami H., Takahashi N., Tanaka S., et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 20:1997;399-404.
59. Niskikawa M., Akatsu T., Katayama Y., et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 18:1996;9-14.
60. Olpas E.E., Rutledge S.J., Golub E., et al. Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem Pharmacol. 54:1997;721-727.
61. Papapoulos S.E. Pharmacodynamics of bisphosphonates in man. Bijvoet O., Fleisch H.A., Canfield R.E., Russell R.G.G. Bisphosphonates on Bone. 1995;Amsterdam, Elsevier Science BV.
62. Papapoulos S.E., Hoekman K., Lowik C.W.G.M., Vermeij P., Bijvoet O.L.M. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res. 4:1988;775-781.
63. Paterson A.D., Kanis J.A., Cameron E.C., et al. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol. 54:1983;121-131.
64. Pelorgeas S., Martin J.-P., Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. Biochem Pharmacol. 44:1992;2157-2163.
65. Ralston S.H., Gallacher S.J., Patel U., Fraser W.D., Dryburgh F.J., Boyle I.T. Comparison of three bisphosphonates in cancer-associated hypercalcaemia. Lancet. 2:1989;1180-1182.
66. Ridley A.J., Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 70:1992;389-399.
67. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell. 70:1992;401-410.
68. Rogers M.J., Brown R.J., Hodkin V., Russell R.G.G., Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun. 224:1996;863-869.
69. Rogers M.J., Chilton K.M., Coxon F., et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells by a nitric-oxide-independent mechanism. J Bone Miner Res. 11:1996;1482-1491.
70. Rogers M.J., Ji X., Russell R.G.G., et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J. 303:1994;303-311.
71. Rogers M., Russell R.G.G., Blackburn G.M., Williamson M.P., Watts D.J. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun. 189:1992;414-423.
72. Rogers M.J., Watts D.J., Russell R.G.G., et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res. 9:1994;1029-1039.
73. Rogers M.J., Watts D.J., Russell R.G.G. Overview of bisphosphonates. Cancer. 80:1997;1652-1669.
74. Rogers M.J., Xiong X., Brown R.J., et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol. 47:1995;398-402.
75. Rogers M.J., Xiong X., Ji X., et al. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res. 14:1997;625-630.
76. Russell R.G.G. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet. 2:1965;461-464.
77. Russell R.G.G., Bisaz S., Donath A., Morgan D.B., Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J Clin Invest. 50:1971;961-969.
78. Russell R.G.G., Muhlbauer R.C., Bisaz S., Williams D.A., Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. J Calcif Tissue Res. 6:1970;83-196.
79. Russell R.G.G., Rogers M.J. Introduction to bisphosphonates and the clinical pharmacology of alendronate. Br J Rheumatol. 36:1997;10-14.
80. Russell R.G.G., Smith R., Preston C., Walton R.J., Woods C.F. Diphosphonates in Paget's disease. Lancet. 1:1974;894-898.
81. Saag K.G., Emkey K., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 339:1998;292-299.
82. Sahni M., Guenther H., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 91:1993;2004-2011.
83. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 5:1990;31-40.
84. Sato M., Grasser W., Endo N., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:1991;2095-2105.
85. Sauty A., Pecherstorfer M., Zimmerroth I., et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone. 18:1996;133-139.
86. Schenk R., Eggli P., Fleisch H., Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 38:1986;342-349.
87. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 11:1973;196-214.
88. Schmidt A., Rutledge S.J., Endo N., et al. Alendronate inhibition of protein tyrosine phosphatase activity. Proc Natl Acad Sci USA. 93:1995;3068-3073.
89. Schweitzer D.H., Oostendorp-van de Ruit M., van der Pluijm G., Lowik C.W.G.M., Papapoulos S.E. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 10:1995;956-962.
90. Selander K.S., Mönkkönen J., Karhukorpi E.-K., Härkönen P., Hannuniemi R., Väänänen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 50:1996;1127-1138.
91. Shipman C.M., Croucher P.I., Russell R.G.G., Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58:1998;5294-5297.
92. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G.G., Croucher P.J. Bisphosphonates induce apoptosis in human myeloma cells; a novel anti-tumour activity. Br J Haematol. 98:1997;665-672.
93. Sietsema W.K., Ebetino F.H., Salvagno A.M., Bevan J.A. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 15:1989;389-396.
94. Smith R., Russell R.G.G., Bishop M. Diphosphonate and Paget's disease of bone. Lancet. 1:1971;945-947.
95. Storm T., Thamsborg G., Steiniche T., et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 322:1990;1265-1271.
96. Suda T., Nakamura I., Jimi E., Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 12:1997;869-879.
97. van Beek E., Lowik C., Oue I., Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res. 11:1996;1492-1497.
98. van Staa T.P., Abenhain L., Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol. 37:1998;87-94.
99. van Staa T.P. Post marketing survey with ICT-etidronate therapy. Rev Contemp Pharmacol. 9:1998;277-286.
100. Vitte C., Fleisch H., Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 137:1996;2324.
101. Watts N.B., Harris S.T., Genant H.K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 323:1990;73-79.
102. Yu X., Scholler J., Foged N.T. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone. 19:1996;339-345.
103. Zerial M., Stenmark H. Rab GTPases in vesicular transport. Curr Opin Cell Biol. 5:1993;613-620.
104. Zhang F.L., Casey P.J. Protein prenylation molecular mechanisms and functional consequences . Annu Rev Biochem. 65:1996;241-249.
105. Zhang D., Udagawa N., Nakamura I., et al. The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci. 108:1995;2285-2292.
106. Zimolo Z., Wesolowski G., Rodan G.A. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest. 96:1995;2277-2283.